These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 20452658)

  • 1. A phase II evaluation of weekly gemcitabine and docetaxel for second-line treatment of recurrent carcinosarcoma of the uterus: a gynecologic oncology group study.
    Miller BE; Blessing JA; Stehman FB; Shahin MS; Yamada SD; Secord AA; Warshal DP; Abulafia O; Richards WE; Van Le L
    Gynecol Oncol; 2010 Aug; 118(2):139-44. PubMed ID: 20452658
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study.
    Hensley ML; Blessing JA; Degeest K; Abulafia O; Rose PG; Homesley HD
    Gynecol Oncol; 2008 Jun; 109(3):323-8. PubMed ID: 18394689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial.
    Hensley ML; Blessing JA; Mannel R; Rose PG
    Gynecol Oncol; 2008 Jun; 109(3):329-34. PubMed ID: 18534250
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Feasibility study of gemcitabine plus docetaxel in advanced or recurrent uterine leiomyosarcoma and undifferentiated endometrial sarcoma in Japan.
    Takano T; Niikura H; Ito K; Nagase S; Utsunomiya H; Otsuki T; Toyoshima M; Tokunaga H; Kaiho-Sakuma M; Shiga N; Nagai T; Tanaka S; Otsuki A; Kurosawa H; Shigeta S; Tsuji K; Yamaguchi T; Yaegashi N
    Int J Clin Oncol; 2014 Oct; 19(5):897-905. PubMed ID: 24149774
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Weekly docetaxel with either gemcitabine or vinorelbine as second-line treatment in patients with advanced nonsmall cell lung carcinoma: Phase II trials of the Minnie Pearl Cancer Research Network.
    Hainsworth JD; Burris HA; Billings FT; Bradof JE; Baker M; Greco FA
    Cancer; 2001 Nov; 92(9):2391-8. PubMed ID: 11745295
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gemcitabine and docetaxel as second-line chemotherapy for patients with nonsmall cell lung carcinoma who fail prior paclitaxel plus platinum-based regimens.
    Kosmas C; Tsavaris N; Vadiaka M; Stavroyianni N; Koutras A; Malamos N; Onyenadum A; Rokana S; Polyzos A; Kalofonos HP
    Cancer; 2001 Dec; 92(11):2902-10. PubMed ID: 11753965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized phase III trial of gemcitabine plus docetaxel plus bevacizumab or placebo as first-line treatment for metastatic uterine leiomyosarcoma: an NRG Oncology/Gynecologic Oncology Group study.
    Hensley ML; Miller A; O'Malley DM; Mannel RS; Behbakht K; Bakkum-Gamez JN; Michael H
    J Clin Oncol; 2015 Apr; 33(10):1180-5. PubMed ID: 25713428
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II study of days 1 and 8 combination of docetaxel plus gemcitabine for the second-line treatment of patients with advanced non-small-cell lung cancer and good performance status.
    Cobo M; Gutiérrez V; Alcaide J; Alés I; Villar E; Gil S; Durán G; Martínez J; Carabantes F; Bretón JJ; Benavides M
    Lung Cancer; 2007 May; 56(2):255-62. PubMed ID: 17276537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Weekly docetaxel and gemcitabine in previously treated metastatic esophageal squamous cell carcinoma.
    Lee MY; Jung KS; Kim HS; Lee JY; Lim SH; Kim M; Jung HA; Kim SM; Sun JM; Ahn MJ; Lee J; Park SH; Yi SY; Hwang IG; Lee SC; Ahn HK; Lim DH; Lee SI; Park KW
    World J Gastroenterol; 2015 Apr; 21(14):4268-74. PubMed ID: 25892878
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II evaluation of paclitaxel and carboplatin in the treatment of carcinosarcoma of the uterus: a Gynecologic Oncology Group study.
    Powell MA; Filiaci VL; Rose PG; Mannel RS; Hanjani P; Degeest K; Miller BE; Susumu N; Ueland FR
    J Clin Oncol; 2010 Jun; 28(16):2727-31. PubMed ID: 20421537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II trial of weekly docetaxel/ gemcitabine as first-line chemotherapy in patients with locally recurrent or metastatic breast cancer.
    O'Shaughnessy JA; Pluenneke R; Sternberg J; Khandelwal P; Ilegbodu D; Asmar L
    Clin Breast Cancer; 2006 Feb; 6(6):505-10. PubMed ID: 16595033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemotherapy with gemcitabine, cisplatin, and docetaxel in the treatment for patients with muscle-invasive bladder cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG).
    Boukovinas I; Androulakis N; Kentepozidis N; Polyzos A; Papakotoulas P; Ziras N; Kotsakis A; Vardakis N; Karampeazis A; Markos V; Kostakopoulos A; Constantinides CA; Samonis G; Mavroudis D; Georgoulias V
    Cancer Chemother Pharmacol; 2012 Feb; 69(2):351-6. PubMed ID: 21748359
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Docetaxel in combination with gemcitabine plus rhG-CSF support as second-line treatment in non-small cell lung cancer. A multicenter phase II study.
    Kakolyris S; Papadakis E; Tsiafaki X; Kalofonos C; Rapti A; Toubis M; Bania E; Kouroussis C; Chainis K; Androulakis N; Agelaki S; Sarra E; Vardakis N; Georgoulias V;
    Lung Cancer; 2001 May; 32(2):179-87. PubMed ID: 11325489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of sequential gemcitabine followed by docetaxel for recurrent Ewing sarcoma, osteosarcoma, or unresectable or locally recurrent chondrosarcoma: results of Sarcoma Alliance for Research Through Collaboration Study 003.
    Fox E; Patel S; Wathen JK; Schuetze S; Chawla S; Harmon D; Reinke D; Chugh R; Benjamin RS; Helman LJ
    Oncologist; 2012; 17(3):321. PubMed ID: 22363068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paclitaxel in the treatment of carcinosarcoma of the uterus: a gynecologic oncology group study.
    Curtin JP; Blessing JA; Soper JT; DeGeest K
    Gynecol Oncol; 2001 Nov; 83(2):268-70. PubMed ID: 11606082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial.
    Seddon B; Strauss SJ; Whelan J; Leahy M; Woll PJ; Cowie F; Rothermundt C; Wood Z; Benson C; Ali N; Marples M; Veal GJ; Jamieson D; Küver K; Tirabosco R; Forsyth S; Nash S; Dehbi HM; Beare S
    Lancet Oncol; 2017 Oct; 18(10):1397-1410. PubMed ID: 28882536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Second-line chemotherapy for non-small-cell lung cancer with monthly docetaxel and weekly gemcitabine: a phase II trial.
    Spiridonidis CH; Laufman LR; Carman L; Moore T; Blair S; Jones J; George C; Patel T; Roach R; Rupert R; Zangmeister J; Colborn D; Kuebler JP
    Ann Oncol; 2001 Jan; 12(1):89-94. PubMed ID: 11249055
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequential gemcitabine and cisplatin followed by docetaxel as first-line treatment of advanced urothelial carcinoma: a multicenter phase II study of the Hellenic Oncology Research Group.
    Boukovinas I; Androulakis N; Vamvakas L; Papakotoulas P; Ziras N; Polyzos A; Kalykaki A; Kotsakis A; Xenidis N; Gioulmbasanis I; Mavroudis D; Georgoulias V
    Ann Oncol; 2006 Nov; 17(11):1687-92. PubMed ID: 16968872
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant therapy for high-grade, uterus-limited leiomyosarcoma: results of a phase 2 trial (SARC 005).
    Hensley ML; Wathen JK; Maki RG; Araujo DM; Sutton G; Priebat DA; George S; Soslow RA; Baker LH
    Cancer; 2013 Apr; 119(8):1555-61. PubMed ID: 23335221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I trial of weekly docetaxel and gemcitabine in patients with refractory malignancies.
    Mekhail T; Hutson TE; Elson P; Budd GT; Srkalovic G; Olencki T; Peereboom D; Pelley R; Bukowski RM
    Cancer; 2003 Jan; 97(1):170-8. PubMed ID: 12491518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.